Company: DAWN
Filing Date: 2025-11-13
Form Type: SC TO-C
Source: 0001104659-25-110815
Chunk: 21

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-11-13
Form: SC TO-C
Chunk 21
---
 by 2037: $6.00 per share One Non - Tradeable Contingent Value Right (CVR) Milestones

Thank You

Exhibit 99.3

| Targeted therapies for people of all ages 
 November 2025                             
 Day One                                   
 Biopharmaceuticals                        |

| 2                                                                                                                                                                                   
 Disclaimer                                                                                                                                                                          
 This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on                         
 information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or               
 quantified. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expect,” “plan,” anticipate,” “believe,”           
 “estimate,” “predict,” “intend,” “potential,” “would,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. Forward-looking statements include     
 all statements other than statements of historical fact contained in this presentation, including information concerning our future financial performance, including the            
 sufficiency of our cash, cash equivalents and short-term investments to fund our operations, business plans and objectives, timing and success of our commercialization and         
 marketing efforts, timing and success of our planned nonclinical and clinical development activities, the success of our proposed acquisition of Mersana Therapeutics and its       
 Emi-Le program, the results of any of our strategic collaborations, including the potential achievement of milestones and provision of royalty payments thereunder, efficacy and    
 safety profiles of our products and product candidates, the ability of OJEMDA (tovorafenib) to treat pediatric low-grade glioma (pLGG) or related indications, the potential        
 therapeutic benefits and economic value of our products and product candidates, potential growth opportunities, competitive position, industry environment and potential            
 market opportunities, our ability to protect intellectual property and the impact of global business or macroeconomic conditions, including as a result of inflation, changing      
 interest rates, government shutdowns, cybersecurity incidents, significant political, trade or regulatory developments, including tariffs, shifting priorities within the U.S. Food 
 and Drug Administration and reduced funding of federal healthcare programs, and global regional conflicts, on our business and operations.                                          
 Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors. It is not possible for our management to predict all risks,        
 nor can we assess the impact of all factors on